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Gastricantralvascularectasiaisanotsowell-understood,andmorerare,gastrointestinalmanifestationofSystemicSclerosiswhich
can lead to chronic anemia. A high suspicion and better understanding of this rare manifestation is needed for early detection and
treatment. Therapeutic regiments include iron supplementation with acid suppressive therapy, while endoscopic intervention has
been shown to be successful in most cases, with gastrectomy or antrectomy rarely needed.
1.Introduction
Gastric antral vascular ectasia (GAVE) was ﬁrst deﬁned in
1984 by Jabbari et al. [1]. Its distinctive endoscopic appear-
ance caused it to be also known as “watermelon stomach.”
Onvisualizationitconsistsofparallelrugalfoldswithdilated
blood vessels going from the gastric antrum and converging
on the pylorus resembling watermelon rind and thus the
nomenclature. It is often found in association with autoim-
mune diseases such as diﬀuse or limited cutaneous systemic
sclerosis (dcSSc or lcSSc), Raynaud’s phenomenon perni-
cious anemia, autoimmune hypothyroidism, primary biliary
cirrhosis, polymyalgia rheumatic, and rheumatoid arthritis,
but it is also found in patients suﬀering from other chronic
medicalconditionssuchascirrhosisoftheliver,chronicrenal
failure, ischemic or valvular heart disease, hypertension,
acute myeloid leukemia, diabetes, and chronic obstructive
pulmonary disease [2].
2. Prevalence and Incidence
GAVE is a rare manifestation of systemic sclerosis. A recent
large retrospective study of 264 patients with SSc found a
prevalence of 5.7% [3]. Eighty to ninety percent of patients
already carry the diagnosis of SSc before GAVE manifests
itself [3], but occasionally it can be the initial manifestation
of the disease [4, 5]. It is commonly diagnosed early in the
course of the disease, often within the ﬁrst 3 years from
diagnosis [3]. Prevalence though may be higher than de-
scribed because patients who undergo endoscopy are only
the ones who are symptomatic or have an unexplained ane-
mia. In a recent abstract from the SCOT trial (Sclero-
derma cyclophosphamide or transplant study), where as-
ymptomatic dcSSc patients had to be screened with an endo-
scopy before entering the study, 10.8% of them had silent
GAVE [6].
3. Risk Factors
In some studies GAVE has been shown to be more prevalent
in lcSSc while in other studies in dcSSc patients [3, 7, 8]. Pa-
tients with dcSSc tend to develop GAVE earlier in their dis-
ease course than patients with lcSSc, often the diagnosis is
made within 2 years from the diagnosis of dcSSc, and in a
recent series of twenty-eight patients with SSc and GAVE pa-
tients with dcSSc were diagnosed at a mean of 21.5 months
intotheirdiseasecoursecomparedto82.6monthsinpatients
with lcSSc. The patients with lcSSc in this series also tended
to have less severe anemia [7]. This may be a reﬂection of the
natural history of lcSSc which has a more indolent course as
compared to dcSSc.
An association between rapidly progressive skin changes
and the development of early onset GAVE (i.e., development
of GAVE within 18 months of the onset of SSc symptoms)
may also exist. A subset of 16 patients from the series of 282 International Journal of Rheumatology
patients in the article by Ingraham et al. were diagnosed with
early-onset GAVE. Nine out of these 16 patients also had
rapid progression of their cutaneous disease (i.e., the pre-
sence of diﬀuse involvement in the upper extremities and
trunk by 18 months from the onset of the ﬁrst SSc symp-
toms) [7]. Ceribelli et al. also suggested that rapid progres-
sion of cutaneous disease is associated with the early devel-
opment of GAVE [9].
Theautoantibodyproﬁlemayalsogivecluestotheriskof
developing GAVE, and a speckled pattern appears to carry a
higher risk [7]. A recent report suggests a possible predictive
role of RNA polymerase III (RNAP III) antibodies for GAVE.
Ceribelli et al. reported 16 SSc patients with positive anti-
RNAP III antibodies; 4 out of the 16 (25%) had GAVE [9].
This is considerably higher than the overall prevalence of
GAVE in SSc patients [3]. It has been shown in several series
thatlackofantitopoisomeraseIantibodies(anti-scl-70)isas-
sociated with an increased risk of GAVE [3, 7, 9].
4. Pathogenesis
The pathogenesis of GAVE is not fully understood though it
has been noted in the past when pathology specimens from
GAVE patients were examined that there is a loose attach-
ment of the distal gastric mucosa to the underlying muscu-
laris externa, where in the setting of dysmotility the antral
mucosa may prolapse through the pylorus [1, 3, 10]. Pathol-
ogy specimens show dilated capillaries, focal ﬁbrin thrombi,
spindle cell proliferation on the mucosal surface, ﬁbromus-
cular hyperplasia in the lamina propria, and dilated submu-
cosal vessels [1, 3, 11].
GAVEisconsideredoneofthemanifestationsofthespec-
trum of vascular alterations in systemic sclerosis [8]. Studies
have shown that the majority of patients with GAVE, around
60%, have telangiectasias of the skin. A smaller percentage
alsohastelangiectasiasinthegastrointestinaltractotherthan
the stomach, in the esophagus, duodenum, ileum, colon,
and rectum [3]. Supporting this theory is the fact that simi-
lar histopathologic changes can be found in the dermis on
skin biopsies of scleroderma patients as are found in gastric
mucosal biopsies from GAVE patients—that is, capillary
dilatation, small vessel ﬁbrin deposits, and platelet throm-
bosis [3, 8].
5. ClinicalEvaluationandDiagnosis
Most patients with lcSSc and GAVE present with iron deﬁ-
ciency anemia or symptoms attributable to iron deﬁciency
anemia, such as weakness, severe fatigue, or dyspnea on ex-
ertion. Thus a high index of suspicion is often needed in
order to make the diagnosis in a timely fashion. Patients with
dcSSc have a tendency to present with occult blood in the
stool, and occasionally one may present with overt gastroin-
testinal bleeding though melena or hematemesis is unusual
[3, 10]. Recurrent indolent bleeding is common, occurring
in approximately one-third of cases [3].
6.Endoscopic Description
The appearance of GAVE is longitudinal red stripes or rugal
folds in the antrum, radiating out in pattern resembling
spokes from the pylorus. Alternatively, multiple cherry-red
spots may be seen, but this mosaic pattern is far less com-
mon. Antral biopsies typically show capillary dilation with
focalintravascularthrombiandﬁbromuscularhyperplasiain
the lamina propria [1].
7. Management
Management of GAVE ranges from conservative sympto-
matic therapy to endoscopic interventions to surgery. The
mainstays of symptomatic therapy and medical management
are iron supplementation, proton pump inhibitors, and
blood transfusion if anemia is severe and symptomatic [3].
There are some reports in the literature of treatment with es-
trogen-progesterone combination hormone therapy, but the
risks and beneﬁts must be carefully weighed in each individ-
u a lc a s e[ 12–14].
Early diagnosis of GAVE in SSc patients is important be-
causeendoscopicmanagementcansuccessfullytreatthis.Itis
important to educate primary care physicians who take care
of these patients to be aware of slight drops in the hemo-
globin of SSc patients and to refer such patients for endo-
scopic evaluation. While lcSSc patients typically have a good
outcome after local therapy, dcSSc are more diﬃcult to treat,
withaneedforrecurrentelectrocoagulationandbloodtrans-
fusions and an increased risk for renal crisis.
Several unique endoscopic interventions have been re-
ported to be successful in the management of GAVE. One
popular technique is argon plasma coagulation, which has
been shown to be eﬀective in short- and medium-term
followup in maintaining a rise in hemoglobin and giving
transfusion independence to formerly transfusion-depend-
ent patients within 2-3 treatment sessions [15]. Occasionally
it can be associated with discomfort from gastric overdisten-
sion with argon gas [16].
Another endoscopic technique is neodymium-yttrium
aluminum garnet (Nd:YAG) laser photocoagulation. A study
of 45 patients treated with Nd:YAG laser reported that, at an
averageoftwo-yearfollowup,normalhemoglobinlevelswere
seenin87%ofallpatientsandtransfusionindependencewas
found in 24 of 28 initially transfusion-dependent patients
[10].
There have been case reports describing many other suc-
cessful therapies such as endoscopic band ligation [17], en-
doscopic ablation with hot biopsy forceps [16], and endo-
scopictherapywithmonopolarelectrocoagulationandinjec-
tion of 5% polidocanol [18].
There have been reports of success in two small series of
patients using intravenous cyclophosphamide to treat sys-
temic sclerosis-associated GAVE or remission of GAVE when
cyclophosphamideisusedtotreatotherseriousdiseaseman-
ifestations such as pulmonary disease [19, 20].
Gastrectomy or antrectomy is the only cure for GAVE,
but it is rarely needed in the modern era with such a vast
array of medical and endoscopic therapies available.International Journal of Rheumatology 3
8. Conclusion
Gastric antral vascular ectasia continues to be a not well-
understood manifestation of SSc patients, but an increase
awareness and early diagnosis can improve outcome since
localtherapycanbesuccessful.Thereisaneedforanoninva-
sive therapy, though currently the best approach in the care
ofthesepatientsisclosefollowupandrepeatedlocaltherapy.
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